MetaCap

Kardigan (KARD) vs Tyra Biosciences (TYRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

Tyra Biosciences is the larger company by market cap ($1.37 billion vs $1.33 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KARD-35.45%TYRA-29.48%
+21%-10%-42%
Jun 18, 20261 yearOct 8, 2026
KARD-35.45%TYRA-29.48%
+18%-10%-38%
Jun 15, 20265 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KARD versus TYRA key metrics
MetricKARDTYRA
Share price$14.20$19.97
Market cap$1.33B$1.37B
1-day change+2.68%-2.06%
YTD return—-24.04%
1-year return—+46.52%
5-year return—+22.22%
EPS (TTM)$-10.65$-2.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$27.00$40.65
52-week low$12.23$13.29
Distance from 52-week high-47.41%-50.87%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+197.54%+137.61%
Average volume483.42K857.13K
Shares outstanding93.50M68.76M
Employees24187
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Kardigan

KARD stock →

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 241 employees

About Tyra Biosciences

TYRA stock →

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

KARD vs TYRA FAQ

Which is bigger, Kardigan or Tyra Biosciences?

Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.37B compared with $1.33B for Kardigan (KARD).

Are Kardigan and Tyra Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons